Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Maxamine progresses to phase III in AML

Feb. 23, 1998

Phase I trial results of DAB389IL-2 in lymphoma

Feb. 20, 1998

Seragen fusion toxin will get priority review

Feb. 5, 1998

Anti-ErbB3 antibodies described by Genentech in patent literature

Feb. 3, 1998

Proleukin cleared for marketing in U.S. for melanoma indication

Jan. 30, 1998

AltaRex reacquires Western European marketing rights to Ovarex

Jan. 27, 1998

New approach to cancer therapy reported

Jan. 27, 1998

Vical receives patent protection for lipid-mediated DNA vaccines

Jan. 8, 1998

Mechanism of TNF-alpha production in tumor tissues by Ono-4007

Jan. 5, 1998

Favorable phase III trial results reported for HER2 monoclonal antibody

Dec. 31, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...